1. Home
  2. NICM vs PMN Comparison

NICM vs PMN Comparison

Compare NICM & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nicola Mining Inc. American Depositary Shares

NICM

Nicola Mining Inc. American Depositary Shares

N/A

Current Price

$5.85

Market Cap

120.4M

Sector

N/A

ML Signal

N/A

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$12.22

Market Cap

136.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NICM
PMN
Founded
N/A
2004
Country
Canada
Canada
Employees
25
N/A
Industry
Pharmaceuticals and Biotechnology
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.4M
136.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
NICM
PMN
Price
$5.85
$12.22
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$42.67
AVG Volume (30 Days)
3.0K
99.3K
Earning Date
N/A
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.77
$0.29
52 Week High
$6.48
$27.40

Technical Indicators

Market Signals
Indicator
NICM
PMN
Relative Strength Index (RSI) 47.97 45.45
Support Level $5.92 $9.87
Resistance Level $6.38 $14.40
Average True Range (ATR) 0.16 1.37
MACD -0.03 -0.23
Stochastic Oscillator 35.34 5.22

Price Performance

Historical Comparison
NICM
PMN

About NICM Nicola Mining Inc. American Depositary Shares

Nicola Mining Inc is a junior exploration and custom milling company that is engaged in the business of identification, acquisition, and exploration of mineral property interests, together with custom milling partnerships at its Merritt Mill. The company holds interests in various claims at the following properties: the Treasure Mountain Property, New Craigmont Property, and Dominion Creek Property. Its portfolio of producing assets and development projects is mainly composed of copper, gold, and silver properties spread across British Columbia, Canada.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: